Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | PTGFR | P43088 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427744 | 1.00 | HDAC1 (0.54) | HDAC1HDAC8EPHX2PTGFRHDAC3 | |
| SCHEMBL30428006 | 0.95 | HDAC1 (0.56) | HDAC1HDAC8EPHX2PTGFRHDAC3 | |
| SCHEMBL29246654 | 0.93 | PTGFR (0.56) | HDAC1HDAC8EPHX2PTGFRHDAC3 | |
| SCHEMBL29733422 | 0.89 | EPHX2 (0.59) | HDAC1HDAC8EPHX2PTGFRFFAR4 | |
| SCHEMBL1953231 | 0.89 | EPHX2 (0.59) | HDAC1HDAC8EPHX2PTGFRFFAR4 | |
| SCHEMBL29009872 | 0.87 | HDAC1 (0.49) | HDAC1HDAC8EPHX2PTGFRHDAC3 | |
| SCHEMBL7505411 | 0.86 | HDAC1 (0.54) | HDAC1HDAC8EPHX2MEN1KMT2A | |
| SCHEMBL29009963 | 0.85 | FFAR4 (0.54) | HDAC1HDAC8EPHX2PTGFRHDAC3 | |
| SCHEMBL31512109 | 0.81 | HDAC3 (0.68) | HDAC1HDAC8HDAC3MAPK1ADRA1A | |
| SCHEMBL2878880 | 0.81 | HDAC3 (0.68) | HDAC1HDAC8HDAC3MAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209433-A | Small molecule albumin binding agents | 俄勒冈健康科学大学 | 2023-06-02 | — | — | CN | disclosed |
| EP-3769776-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-2822572-B1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-110914241-A | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3432904-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| WO-2018165575-A2 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-09-13 | — | — | WO | disclosed |
| EP-3347372-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | Aileron Therapeutics, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3294318-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017165299-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-3197478-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2013059525-A1 | PEPTIDOMIMETIC MACROCYLES | AILERON THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012173846-A2 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012166387-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-8222281-B2 | Carboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| US-7956054-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| CN-102076650-A | Carboxylic acid compound | DAIICHI SANKYO CO LTD | 2011-05-25 | — | — | CN | disclosed |
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
| EP-2054390-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPV1 AND USES THEREOF | Abbott Laboratories (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008024945-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | AKR1C3, SLC5A1, GPR119 | HDAC1 379/4885HDAC8 1499/4885EPHX2 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.